Introduction
Rett syndrome (RTT) is a neurodevelopmental disorder that affects the patient's ability to communicate and perform simple motor tasks. RTT affects mainly females, occurring with an incidence of up to 1:10,000 (1,2). Although the RTT phenotype is variable, most Rett patients have a distinctive disease course. They appear to develop normally from birth to about 6 to 18 months. After this initial apparently normal period, patients undergo a period of regression characterized by the loss of acquired speech, deceleration of head growth, and the development of ataxia, seizures, scoliosis, breathing dysfunction and autistic behavior (3). A stereotyped repetitive hand-washing or hand-wringing gesture replaces purposeful use of the hands. After this regressive phase, patients stabilize but fail to acquire new skills and may also develop additional neurological abnormalities (3).
The vast majority of Rett cases are caused by mutations in the MECP2 gene (4). MECP2, which maps to Xq28 and is not expressed from the inactive X chromosome, encodes for methyl-CpG-binding protein 2 (MeCP2). MeCP2 is a methylation dependent transcriptional repressor (5) and a splicing regulator (6) most abundant in brain, lung and spleen (7). In the mature brain, MeCP2 is present in virtually every neuron. The spectrum of MECP2 mutations causing Rett syndrome includes missense, frameshift and nonsense mutations, and intragenic deletions (2).
Mouse models of the disease had been generated using gene targeting approaches. Mice null for Mecp2 exhibit clinical manifestations of Rett: a period of apparently normal development followed by a severe progressive neurological dysfunction that includes abnormal gait and movements, irregular breathing, tremors and hypoactivity. They exhibit alterations in synaptic plasticity and males die at ~8-12 weeks of age (8) (9) (10) . In addition, we have generated a mouse model of Rett by truncating the Mecp2 gene after aminoacid 308 (full length is 486aa). Male mutant mice survive to adulthood and show features of Rett in a progression that mimics the human disease. Mecp2 308/y mice show stereotypic forelimb motions, tremor, motor and social behavioral abnormalities, seizures, hypoactivity, anxiety-like behavior and learning and memory deficits (11) (12) (13) .
The initial period of apparent normal development displayed by RTT patients suggests that MeCP2 expression might be unessential in the developing brain. This is supported by the observation that the timing of MeCP2 expression in mouse and human correlates with the maturation of the central nervous system (7, 14) . For example, MeCP2 levels in olfactory neurons become maximal after synaptogenesis (15) , and deletion of Mecp2 in postnatal CNS neurons reproduces the phenotypes of MeCP2 null mice (8, 9) .
Furthermore, expression of wild type MeCP2 in postmitotic neurons under the control of a neuron-specific promoter rescued the phenotype of the Mecp2 null mice (16) , strengthening the hypothesis of the dispensability of MeCP2 for normal development and indicating that the phenotype is caused by MeCP2 deficiency in the CNS. These data also suggest that the progression of Rett can be halted or reversed by restoring MeCP2 function, or the function of its downstream effectors. In fact, it has been recently reported that most of the Rett-like phenotypes exhibited by Mecp2 null mice are reversible, indicating that the dysfunctional neuronal network could be rescued by the sole expression of MeCP2 (17) .
We set out to evaluate if the restoration of functional MeCP2 in a subset of neurons was sufficient to rescue the phenotypic manifestations of MeCP2 mutant mice, with the reasoning that restoring the function of the protein in specific neurons might prevent phenotypes resulting from dysfunction of such neurons. 
Results

Generation of a mouse with an inducible wild-type MECP2 allele.
This work was initiated as an effort to determine whether the Rett-like disease in the Mecp2 mutant mice models was reversible and the period of development during which therapeutic intervention could be successful. To answer these questions, we generated mice transgenic for an inducible wild-type MECP2 allele that when introduced into a Mecp2 mutant background would allow us to evaluate the phenotypic rescuing effects of wild-type MeCP2 expression at different stages of disease progression. Cell-specific transgenic MeCP2 expression, also able to be temporally regulated, was achieved with a system based on the tetracycline-transactivator (tTA), a fusion protein between the tetracycline repressor TetR and a minimal transactivation domain of the viral VP16
protein.
In the absence of tetracycline, tTA (encoded in one transgene) binds to tetO recognition sequences in the tetracycline-responsive element (TRE) adjacent of a CMV minimal promoter, and activates RNA polymerase II-dependent transcription of MeCP2
and EGFP simultaneously (all contained in a second transgene). If tetracycline is present, tTA dissociates from the TRE and transcription ceases. We constructed MECP2-pBI-EGPF, a bi-directional construct designed to allow the simultaneous regulation of both MeCP2 (wild type) and EGFP by a central tetracycline-responsive element ( Figure 1A ).
From ten transgenic founders, with transgene copy number ranging from 5 to 15 copies, only six transmitted the transgene to their F1 progeny. MeCP2 should not be expressed from the transgene in these mice unless binding of the tetracycline-inhibitable transcription factor (tTA) is provided. Therefore, the six transgenic lines were crossed with mice expressing the tetracycline-inhibitable transcription factor (tTA) under the control of brain-specific promoters (CamKII-tTA or Eno2-tTA). The particular CamKIItTA and Eno2-tTA transgenic lines that we used in this study have been shown to direct Cell-specific expression of transgenic MeCP2.
Examination of the tissue specificity for transgene expression indicated that the pattern of expression is dictated by the corresponding brain specific promoter (CamKII or Eno2).
When crossed with CamKII-tTA transgenics, all of the lines express transgenic MeCP2
and EGFP specifically in neurons of the forebrain (Figure 2A ). On the other hand, when tTA is under the expression of the neuron specific enolase promoter (Eno2-tTA transgenics), the expression was specific for the striatum and cerebellum ( Figure 2B ), with the exception of the MeCP2tg20 in which expression extends into the eyes.
Transgene expression was abolished in the presence of doxycycline (supplementary ( Figure 3C ).
Effect of the MECP2 transgene on the phenotype of Mecp2
308/Y mice.
The phenotypes in the Mecp2
308/Y mice are progressive and take months to develop (7,12). To determine whether the tissue-specific expression of transgenic MeCP2 resulted in prevention of development of Rett-like phenotypes, we followed the course of the IMeCP2; Mecp2 308/Y mice for a full year.
We and others have reported that mild overexpression of MeCP2 causes a neurologic phenotype (16, 18 Figure 4C ). Expression of MeCP2 from either the CamKII or the Eno2 promoter did not result in a significant improvement on this task ( Figure 4C ).
We hypothesized that the lack of prevention by constitutive, cell-specific expression of the wild type transgenic MeCP2 could be due to a dominant negative interference from 
Discussion
Our rationale to pursue cell-specific rescue was inspired by the need to determine if any of the Rett syndrome phenotypes originate from specific neurons. Defining such neurons might help in future design of effective therapies.
As a first step towards this goal, and based on previous reports indicating that MeCP2 expression in all neurons was capable of preventing the appearance of phenotypic manifestations in mice with mutant endogenous Mecp2 (16,18), we bred transgenic mice expressing MeCP2 conditionally in specific areas of the brain to mouse models of Rett.
These transgenic lines, express different levels of MeCP2 in different regions of the brain in a regulated manner, and lack overt phenotypic manifestations. Thus they represent a great tool to test the hypothesis that Rett syndrome phenotypes originating in different neurons may be reversible.
To our surprise, however, region-specific expression of transgenic MeCP2 was not able to prevent the development of most of the assessed phenotypes notwithstanding the specific pattern of expression of the transgene. Thus, the inability of constitutive, cell Expression of the transgene in the striatum and cerebellum, whose dysfunction may contribute to the deterioration of the motor system seen in patients with Rett syndrome, did not prevent appearance of the phenotype either.
In our transgenics, only one of the two splice variants identified is expressed (MeCP2-e2) (32, 33) . This should not be a problem, however, since a pan-neuronal postmitoticallyexpressed Mecp2-e2 transgene, encoding solely the splice variant expressed by our transgene, was able to prevent the development of phenotypes of Mecp2 null mice (18) .
Also, the lack of phenotype prevention is probably not due to species-specific differences in the human and mouse proteins, since we have previously shown that expression of transgenic human MeCP2 was able to prevent lethality in Mecp2 null mice (16).
An explanation for the inability of the CamKII or Eno2 driven transgene to prevent the phenotypes of the Mecp2 mutants might be that the levels of transgene expression are not suitable to achieve full MeCP2 function. Although the level of expression of one of the transgenic lines analyzed is similar to the endogenous expression of MeCP2 as measured by western blot, the amount of endogenous MeCP2 is variable depending on the neurons considered, and the expression of the transgenic MeCP2 does not recapitulate this variable pattern, generating cell-specific deficits and excesses in transgene expression levels. Alternatively, brain areas such as the midbrain, or the brain stem, in which the transgenes are not expressed in our mice, might be "the" relevant areas for Rett syndrome clinical manifestations (34, 35) . The latter possibility is less likely given that CamKII-Cre deletion of MeCP2 suffices to cause a Rett-like phenotype. Therefore, the data suggest that Rett is caused by disruption of a neuronal network that includes the CamKII "domain" but also extends outside of it. Thus, restoration of MeCP2 in only a portion of the network is not enough to rescue the complete function of the network while perturbation of particular components of the network suffices to alter its function. Hence, a more widespread expression of MeCP2 in the central nervous system might be necessary to obtain full rescue.
Our data differ markedly with a recent report of CamKII promoter-directed reactivation of MeCP2 at postnatal day 15 that resulted in partial amelioration of Rett-like symptoms and a small extension of life span (36). The discrepant results could stem from the use of different mutant alleles; the Mecp2 null mice that we used in this study lacked exons 3 and 4, while Giacometti et al used mice with deleted exon 3. In addition, the activity and cellular specificity of the CamKII transgenic promoters used in the two studies could differ due to different sites of transgene integration, and dissimilar transgene composition and copy number, factors known to affect transgene expression (37). Also, strain background differences could account for the dissimilar results.
Our results indicate that phenotypes in patients with Rett syndrome either result from dysfunction of neurons in the brain stem and hypothalamus, or from dysfunction of a neuronal network that involves neurons located throughout the brain.
Materials and Methods
Transgenic mice
The MeCP2-pBi-EGFP transgene was generated by subcloning a full-length human MeCP2 cDNA into the pBI-EGFP vector (Clontech). Subsequently, MeCP2-pBI-EGPF was inserted between insulators into pJ13-1, and linearized to release vector sequences.
The linear fragment was introduced into pronuclei of FVB mice by microinjection. 
Behavioral Testing Stereotypic forepaw movements
Mice were suspended by the tail for 10 s and the presence or absence of stereotypic forepaw movements was scored.
Body tremor
Mice were held on the hand of the examiner for 10 s and the presence or absence of body tremor was recorded.
Suspended Wire Test
Mice were suspended by their forepaws on a 2 mm wire, and the amount of time they remained on the wire was recorded. Statistical significance was determined using a Student's t-test.
Rotating Rod Test
Mice were placed on the accelerating rotarod apparatus (Ugo Basile) for twelve trials (three trials on four consecutive days) with a 30-60 min rest interval between trials. Each trial lasted for a maximum of 10 min, during which the rod accelerated linearly from 3 to 30 rpm. The amount of time for each mouse to fall from the rod was recorded for each trial. If the mouse held on to the rod and passively rotated 360°, the time of the second rotation was reported as the time of falling off the rod. Analysis was performed using a two-way ANOVA (genotype × trial) with repeated measures (VassarStats).
Dowel Test
Mice were placed in the center of a horizontal dowel (0.7 cm diameter), and the time they remained on the dowel was recorded. If mice walked across and off of the dowel, they were placed back onto the dowel. Trials lasted for a maximum of 2 min. Data was analyzed using a Student's t-test. performance. Animals performed 3 trials a day for 4 days. For each trial, the mouse was placed on the rotating rod, its head directed against the direction of rotation. The amount of time the animal spent walking on the accelerating rod was recorded. The trial was stopped either when the mouse fell, held passively on to the rod for two consecutive cycles, or after 10 min. Rotarod performance improved in consecutive trials in all genotypes but was impaired in the mutant mice compared to the control mice, regardless of transgene expression (rm-ANOVA, genotype effect P < 0.05, trial effect P < 0.001).
Novel arena Test
The number of animals for each assay is between brackets either below each genotype bar (A and B) or beside genotype legends (C). All data expressed as means ± SEM. 
